Metachronous Gastric Cancer Outcomes After Helicobacter pylori Therapy and Endoscopic Dysplasia Resection: Insights From a Global Real-World Study
We read with interest the article by Yoo et al1 that describes the incidence of metachronous gastric cancer (MGC) after Helicobacter pylori therapy and endoscopic dysplasia resection using data from the Korean nationwide insurance database. The cohort receiving H pylori therapy experienced a significantly lower incidence of MGC compared with the untreated cohort, specifically 5.89 vs 6.20 for MGC and 7.23 vs 9.20 for metachronous gastric neoplasm per 1000 person-years. Several points merit further discussion.
